TB-500 research: what was measured, and on which molecule.

The mechanism: 1:1 actin sequestration

The TB-500 research record starts with structure. X-ray crystallography of a gelsolin-domain-1–Tβ4 hybrid bound to actin, resolved at 2 Å, showed that thymosin beta-4 forms a 1:1 complex with G-actin and sequesters the monomer by capping both ends, preventing polymerization; the WH2 actin-interacting motif underlies this ^[1]. The LKKTETQ sequence carried by TB-500 is that motif.

This is the cleanest, most established fact in the file: not an outcome in an animal, but a solved structure explaining how the parent protein buffers the cell's pool of unpolymerized actin. From there the cell-biology cascade follows — migration, angiogenesis, survival signaling — and so does the central caveat, because the structure was solved on the actin-binding region in the context of the protein, not on the acetylated 7-mer dosed systemically.

Cardiac and survival signaling

In mice, thymosin beta-4 formed a functional complex with PINCH and integrin-linked kinase (ILK), activating the survival kinase Akt; it promoted cardiac and endothelial cell migration and, after coronary artery ligation, upregulated ILK/Akt, enhanced early myocyte survival, and improved cardiac function ^[2]. That 2004 finding is a large part of why thymosin beta-4 entered cardiac drug development at all.

The record is honest about limits. Systemic Tβ4 failed to attenuate myocardial ischemia-reperfusion injury in a porcine study, and human cardiac evidence is confined to a registered acute-myocardial-infarction trial of Tβ4 that completed ^[10]. None of this is fragment data.

Does TB-500 affect the heart?

In mice, thymosin beta-4 activated PINCH–ILK–Akt survival signaling and improved cardiac function after coronary ligation ^[2]; however, systemic Tβ4 failed to attenuate ischemia-reperfusion injury in a porcine study, and human cardiac data are limited to a completed registered acute-MI trial ^[10]. The 7-mer has no cardiac human data.

Wound healing and re-epithelialization

In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, increased wound contraction by at least 11% by day 7, and raised collagen deposition and angiogenesis; as little as 10 pg stimulated keratinocyte migration two- to three-fold ^[3]. These are among the most-cited TB-500–adjacent numbers, and they are full-length Tβ4 figures.

Does TB-500 help wound healing?

Full-length thymosin beta-4 accelerated re-epithelialization, contraction, collagen deposition, and angiogenesis in animal wound models and in topical ophthalmic trials ^[3][5]; a synthetic actin-binding-domain peptide reproduced some of this activity, but human data for the fragment are absent.

How long does TB-500 take to work?

No validated human timeline exists. In a rat wound model, full-length Tβ4 raised re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline ^[3], but animal kinetics do not translate to a human dosing schedule.

Can TB-500 help tendon and ligament repair?

Thymosin beta-4 has been studied in connective-tissue repair as part of its broad migration-and-angiogenesis profile ^[5], but there is no controlled human tendon or ligament data for the fragment, and direct connective-tissue findings are limited.

Neurological models and the non-monotonic dose

In male Wistar rats with embolic middle cerebral artery occlusion, intraperitoneal thymosin beta-4 (2, 12, and 18 mg/kg, started 24 hours post-stroke then every 3 days for four more doses) improved neurological function at 2 and 12 mg/kg — significant from day 14 through day 56 — while 18 mg/kg gave no significant benefit; a modeled optimal dose of roughly 3.75 mg/kg was proposed ^[4].

The non-monotonic shape matters. Higher was not better; the highest dose lost the effect. That single result undercuts the "loading" rationale that circulates in peptide-research communities, which assumes more is more.

Does TB-500 have neuroprotective effects?

In a rat embolic-stroke dose-response study, intraperitoneal Tβ4 improved neurological function at 2 and 12 mg/kg but not at 18 mg/kg (non-monotonic), with a modeled optimum near 3.75 mg/kg ^[4]. An injectable human stroke trial of Tβ4 was withdrawn ^[11].

Muscle, exercise recovery, and the mixed signal

The recovery interest in TB-500 rests on the protein's role in muscle. Thymosin beta-4 acts as a myoblast chemoattractant after muscle injury — but the most relevant chronic study tempers the narrative.

Does TB-500 work for muscle recovery?

Muscle-injury-induced Tβ4 acts as a myoblast chemoattractant in rodents, but a six-month study in dystrophin-deficient (mdx) mice found more regenerating fibers without gains in muscle strength, cardiac function, or fibrosis ^[5]. No controlled human exercise-recovery data exist for the fragment.

TB-500 side effects and safety signals in the literature

Human safety data for the TB-500 side effects profile are scarce, and what exists is for the protein, not the fragment. In a randomized, placebo-controlled Phase 1 study, intravenous synthetic Tβ4 in 40 healthy volunteers — single dose then daily for 14 days at 42, 140, 420, or 1260 mg — was well tolerated, with only infrequent mild-to-moderate adverse events and no dose-limiting toxicities or serious adverse events; pharmacokinetics were dose-proportional with half-life increasing with dose ^[6].

The principal theoretical concern is not an acute side effect but a long-horizon one. Thymosin beta-4 is overexpressed in several cancers and is implicated in metastasis and tumor angiogenesis; the same pro-migratory, pro-angiogenic properties that aid repair could, in principle, support tumor progression ^[5]. A 2026 narrative review listing TB-500 and thymosin beta-4 among unapproved peptides concluded that many show favorable tissue-repair outcomes in animal models but that rigorous human safety data are scarce, with potential for serious harm, and that such compounds operate largely outside regulatory oversight ^[12].

Does TB-500 cause cancer or promote tumor growth?

Thymosin beta-4 is overexpressed in several cancers and implicated in metastasis and tumor angiogenesis; the same pro-migratory and pro-angiogenic properties that aid repair could theoretically support tumor progression ^[5]. This is an unresolved safety concern, not a demonstrated effect of the fragment in humans.

What are the side effects of TB-500?

Human safety data for the fragment are scarce. Full-length Tβ4 was well tolerated to 1260 mg IV in a Phase 1 study ^[6]; the principal theoretical concern is the pro-angiogenic and pro-migratory tumor signal ^[5], and research-grade purity is a recurring issue.

Is TB-500 safe for long-term use?

There are no long-term human safety data for the TB-500 fragment. The longest controlled exposure is a 14-day IV Phase 1 study of full-length Tβ4 ^[6]; the tumor and angiogenesis signal makes chronic use an open question ^[5][12].

Human clinical data: where it exists, and where it stopped

There are no completed controlled clinical trials of the TB-500 heptapeptide for any indication ^[11]. Human data exist only for full-length thymosin beta-4. The Phase 1 intravenous safety and pharmacokinetics study established tolerability to 1260 mg ^[6]. A completed dry-eye trial evaluated topical Tβ4 ophthalmic solution (RGN-259, the ARISE program) ^[7][9], and corneal work showed Tβ4 suppressing NF-κB in the eye ^[8].

The pipeline is also where the optimistic narrative breaks. A registered acute-MI trial of Tβ4 completed ^[10], but an early trial of injectable Tβ4 for acute stroke was withdrawn ^[11] — it did not proceed. Presenting TB-500 as a molecule with a maturing human clinical program overstates the record.

Are there human clinical trials on TB-500?

There are no completed controlled trials of the TB-500 heptapeptide. Human data exist only for full-length thymosin beta-4: a randomized Phase 1 IV safety study ^[6] and topical ophthalmic trials ^[7]; a registered injectable acute-MI trial completed ^[10], and an early injectable stroke trial was withdrawn ^[11].

How does TB-500 differ from BPC-157?

On TB-500 and BPC-157: they are unrelated peptides studied separately. TB-500 is the Ac-LKKTETQ fragment of thymosin beta-4, an actin-binding peptide ^[1]; BPC-157 is a distinct gastric pentadecapeptide. They share no sequence, no parent protein, and no mechanism. What they share is regulatory and evidentiary company — both are unapproved, both are research compounds whose record is dominated by animal data, and both appear on the same FDA advisory-committee agenda as substances under evaluation [reg2]. This site treats only TB-500; BPC-157 is named here for contrast, not as a recommendation.